Li Songhang, Zhao Yuxuan, Lyu Xiaoying, Chen Ye, Zhang Tao, Lin Shiyu, Liu Zhiqiang, Cai Xiaoxiao, Tian Taoran, Lin Yunfeng
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, P. R. China.
Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, Shanghai, 200011, P. R. China.
Adv Sci (Weinh). 2025 Mar;12(10):e2411210. doi: 10.1002/advs.202411210. Epub 2024 Dec 24.
MicroRNA (miRNA)-based therapy holds significant potential; however, its structural limitations pose a challenge to the full exploitation of its biomedical functionality. Framework nucleic acids are promising owing to their transportability, biocompatibility, and functional editability. MiRNA-125 is embedded into a nucleic acid framework to create an enzyme-responsive nanoparachute (NP), enhancing the miRNA loading capacity while preserving the attributes of small-scale framework nucleic acids and circumventing the uncertainty related to RNA exposure in conventional loading methods. An enzyme-sensitive sequence is designed in NP as a bioswitchable apparatus for cargo miRNAs release. NP is compared with conventional delivery modes and delivery vehicles, confirming its excellent transportability and sustained release properties. Moreover, NP confers good enzyme and serum resistance to the cargo miRNAs. Simultaneously, it can easily deliver miRNA-125 to liver and kidney lesions owing to its passive targeting properties. This allows for Keap1/Nrf2 pathway regulation and p53 protein targeting in the affected tissues. Additionally, NP negatively regulates the expression of Bax and Caspase-3. These combined actions help to inhibit oxidation, prevent cell cycle arrest, and reduce the apoptosis of liver and kidney cells. Consequently, this strategy offers a potential treatment for acute liver and kidney injury.
基于微小RNA(miRNA)的疗法具有巨大潜力;然而,其结构局限性对充分发挥其生物医学功能构成了挑战。框架核酸因其可运输性、生物相容性和功能可编辑性而颇具前景。将miRNA - 125嵌入核酸框架中,构建一种酶响应性纳米降落伞(NP),在保留小规模框架核酸特性的同时提高miRNA负载能力,并规避传统负载方法中与RNA暴露相关的不确定性。在NP中设计了一个酶敏感序列作为货物miRNA释放的生物可切换装置。将NP与传统递送模式和递送载体进行比较,证实了其出色的运输能力和缓释特性。此外,NP赋予货物miRNA良好的酶抗性和血清抗性。同时,由于其被动靶向特性,它能够轻松地将miRNA - 125递送至肝肾损伤部位。这使得在受影响组织中能够调节Keap1/Nrf2通路并靶向p53蛋白。此外,NP负向调节Bax和Caspase - 3的表达。这些联合作用有助于抑制氧化、防止细胞周期停滞并减少肝肾细胞的凋亡。因此,该策略为急性肝肾损伤提供了一种潜在的治疗方法。